Fate Therapeutics (FATE) Interest Expenses (2013 - 2019)

Fate Therapeutics (FATE) has 15 years of Interest Expenses data on file, last reported at $116.6 million in Q1 2026.

• Quarterly Interest Expenses fell 10.27% year-over-year to $116.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $116.6 million (down 10.27% YoY) and the FY2025 annual result came in at $388.0 million, up 7.15% from the prior year.
• Interest Expenses rose to $116.6 million in Q1 2026, from $43.1 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $362.1 million in Q4 2024 to a low of $10.9 million in Q2 2025.
• A 5-year average of $138.5 million and a median of $123.3 million in 2025 frame the typical range for Interest Expenses.
• Annual changes were most pronounced in 2023 — Interest Expenses soared 312.74% — and 2025, when it plunged 92.98%.
• Tracing FATE's Interest Expenses over 5 years: stood at $296.2 million in 2022, then gained by 9.36% to $324.0 million in 2023, then increased by 11.77% to $362.1 million in 2024, then plunged by 88.09% to $43.1 million in 2025, then soared by 170.29% to $116.6 million in 2026.
• The last three Interest Expenses figures came in at $116.6 million (Q1 2026), $43.1 million (Q3 2025), and $10.9 million (Q2 2025), per Business Quant data.